{"id":63742,"date":"2026-04-22T22:22:22","date_gmt":"2026-04-22T14:22:22","guid":{"rendered":"https:\/\/flcube.com\/?p=63742"},"modified":"2026-04-22T22:22:23","modified_gmt":"2026-04-22T14:22:23","slug":"novabio-therapeutics-and-obio-tech-strengthen-partnership-to-advance-treg-cell-therapies-for-neurodegenerative-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63742","title":{"rendered":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases"},"content":{"rendered":"\n<p><strong>Novabio Therapeutics<\/strong> and <strong>OBiO Tech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688238:SHA\">SHA: 688238<\/a>) have expanded their strategic collaboration to accelerate the <strong>clinical translation and industrialization of regulatory T cell (Treg) therapies<\/strong>, with a focus on treating <strong>neurodegenerative diseases<\/strong> including <strong>amyotrophic lateral sclerosis (ALS)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profiles-amp-strategic-alignment\">Company Profiles &amp; Strategic Alignment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Focus Area<\/th><th>Key Achievements<\/th><th>Role in Partnership<\/th><\/tr><\/thead><tbody><tr><td><strong>Novabio Therapeutics<\/strong><\/td><td>Treg cell therapy development<\/td><td>Three NMPA IND approvals; global differentiation in neurodegenerative disease treatment<\/td><td>Technology innovation and therapeutic development<\/td><\/tr><tr><td><strong>OBiO Tech, Inc.<\/strong><\/td><td>Cell and gene therapy CDMO services<\/td><td>Leading CDMO in China&#8217;s CGT sector<\/td><td>Manufacturing, process development, and commercialization support<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Founded in 2023, Novabio has rapidly established itself as an innovator in the emerging field of Treg cell therapy, securing regulatory approvals for three investigational new drug applications from China&#8217;s National Medical Products Administration (NMPA). The company&#8217;s focus on neurodegenerative conditions represents a novel application of cellular immunotherapy beyond traditional autoimmune and transplant indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-significance\">Partnership Significance<\/h2>\n\n\n\n<p>The strengthened collaboration leverages Novabio&#8217;s proprietary Treg cell technology platform with OBiO Tech&#8217;s specialized contract development and manufacturing organization (CDMO) capabilities in the cell and gene therapy space. This integrated approach addresses critical challenges in scaling complex cellular therapies from clinical proof-of-concept to commercial viability.<\/p>\n\n\n\n<p>&#8220;Treg cell therapies represent a paradigm shift in treating neurodegenerative diseases by modulating the underlying inflammatory processes that drive disease progression,&#8221; said a Novabio spokesperson. &#8220;Our partnership with OBiO Tech ensures we can maintain the highest quality standards while scaling our manufacturing capabilities to meet future clinical and commercial demands.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p>With neurodegenerative diseases affecting over 50 million people globally and limited effective treatment options available, Treg cell therapy offers a promising approach to address the root causes of conditions like ALS. The Chinese biotech ecosystem&#8217;s growing expertise in advanced therapy medicinal products (ATMPs) positions this collaboration to potentially deliver first-in-class treatments to patients with high unmet medical needs.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development timelines and commercial prospects. Actual outcomes may differ based on clinical trial results, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63743,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,4708,703,1341],"class_list":["post-63742","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-novabio-therapeutics","tag-obio-technology","tag-sha-688238"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate the clinical translation and industrialization of regulatory T cell (Treg) therapies, with a focus on treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63742\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases\" \/>\n<meta property=\"og:description\" content=\"Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate the clinical translation and industrialization of regulatory T cell (Treg) therapies, with a focus on treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63742\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-22T14:22:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-22T14:22:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases\",\"datePublished\":\"2026-04-22T14:22:22+00:00\",\"dateModified\":\"2026-04-22T14:22:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2205.webp\",\"keywords\":[\"Cell-therapy\",\"Novabio Therapeutics\",\"OBiO Technology\",\"SHA: 688238\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63742#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63742\",\"name\":\"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2205.webp\",\"datePublished\":\"2026-04-22T14:22:22+00:00\",\"dateModified\":\"2026-04-22T14:22:23+00:00\",\"description\":\"Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate the clinical translation and industrialization of regulatory T cell (Treg) therapies, with a focus on treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63742\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63742#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate the clinical translation and industrialization of regulatory T cell (Treg) therapies, with a focus on treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63742","og_locale":"en_US","og_type":"article","og_title":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases","og_description":"Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate the clinical translation and industrialization of regulatory T cell (Treg) therapies, with a focus on treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).","og_url":"https:\/\/flcube.com\/?p=63742","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-22T14:22:22+00:00","article_modified_time":"2026-04-22T14:22:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63742#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63742"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases","datePublished":"2026-04-22T14:22:22+00:00","dateModified":"2026-04-22T14:22:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63742"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63742#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp","keywords":["Cell-therapy","Novabio Therapeutics","OBiO Technology","SHA: 688238"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63742#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63742","url":"https:\/\/flcube.com\/?p=63742","name":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63742#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63742#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp","datePublished":"2026-04-22T14:22:22+00:00","dateModified":"2026-04-22T14:22:23+00:00","description":"Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate the clinical translation and industrialization of regulatory T cell (Treg) therapies, with a focus on treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63742#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63742"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63742#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp","width":1080,"height":608,"caption":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63742#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63742"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63742\/revisions"}],"predecessor-version":[{"id":63744,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63742\/revisions\/63744"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63743"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}